Quote from Alex bobby on May 1, 2025, 4:40 AM

Semaglutide Shows Promise for Treating MASH: A Potential Breakthrough in Liver Disease Management

A recent clinical trial has sparked optimism among liver disease experts, as the weight-loss drug semaglutide has shown “hugely exciting” results in treating a serious liver condition known as MASH—metabolic dysfunction-associated steatohepatitis. While no medications are currently approved in the European Union to treat MASH, this new study suggests that semaglutide could soon fill a critical gap in care.

Published in the New England Journal of Medicine, the study offers compelling evidence that semaglutide—currently used to treat obesity and type 2 diabetes—may also benefit patients with MASH, a condition marked by fat buildup in the liver, inflammation, and scarring. If left untreated, MASH can lead to cirrhosis, a form of permanent liver damage. Unlike alcohol-related liver disease, MASH is linked to metabolic issues such as obesity, high blood pressure, and type 2 diabetes.

A Promising Clinical Trial

The late-stage trial was conducted by Novo Nordisk, the pharmaceutical company behind Ozempic and Wegovy, both of which contain semaglutide. The trial enrolled 800 patients diagnosed with MASH and moderate to advanced liver fibrosis, a build-up of scar tissue in the liver.

After 72 weeks of weekly semaglutide injections, 33% of participants experienced significant improvements in both liver inflammation and scarring. When evaluated separately, 63% saw reduced inflammation, and 37% had improved scarring. In contrast, those in the placebo group showed rates of 34% and 22%, respectively.

In addition to liver-related improvements, participants taking semaglutide lost an average of 10.5% of their body weight—a meaningful figure given the strong correlation between obesity and liver disease progression.

Dr. Debbie Shawcross, professor of hepatology at King’s College London and vice secretary general of the European Association for the Study of the Liver, described the results as “hugely exciting.” However, she cautioned that lifestyle counselling also played a role in both groups, suggesting that semaglutide should be viewed as part of a broader treatment approach rather than a standalone solution.

Lifestyle Interventions Still Key

One notable finding from the trial is that 34% of participants in the placebo group also saw a reduction in liver inflammation, despite not receiving the active drug. Many of these individuals made lifestyle changes, underscoring the importance of diet and exercise in managing MASH.

“This is important as any therapy that is licensed for MASH with moderate too severe fibrosis must be used in conjunction with lifestyle interventions,” said Shawcross, who was not involved in the study. She warned that in real-world settings, patients often fail to maintain healthy lifestyle changes, especially after stopping medications. This poses a challenge for long-term disease management and could limit the drug’s effectiveness outside clinical trials.

The combination of medication and lifestyle support may be essential to realising the full potential of treatments like semaglutide. Shawcross emphasized that while semaglutide is a valuable addition to the medical toolkit, it is not a magic bullet.

Side Effects and Future Outlook

While semaglutide’s results are promising, they were not without drawbacks. Patients in the treatment group reported side effects such as nausea, vomiting, diarrhoea, and constipation. These adverse effects caused 2.6% of participants to withdraw from the study.

Novo Nordisk has already submitted regulatory requests in both the EU and US, hoping to secure approval for semaglutide as a treatment for MASH by mid-2025. When the company released the trial’s initial results in November 2024, Dr. Martin Holst Lange, a Novo Nordisk executive, stated that semaglutide could meet a “significant unmet need” for MASH patients.

As of now, the company has not provided further updates on the regulatory timeline, but the medical community remains hopeful. If approved, semaglutide would become the first drug available in the EU for treating MASH, a milestone in the field of hepatology.

Other treatments are also on the horizon. The drug resmetirom, which showed improvement in liver scarring in a previous trial, has already been approved in the United States and is under review by EU authorities.

The Road Ahead

The arrival of semaglutide as a potential treatment for MASH could mark a turning point in the fight against liver disease. However, experts urge caution. As Dr. Shawcross pointed out, many clinical trial participants receive close monitoring and are highly motivated to make lifestyle changes—conditions that are hard to replicate in everyday medical practice.

Ultimately, while semaglutide is a powerful tool, its true success will depend on a patient’s willingness to embrace long-term changes in diet, exercise, and overall health. The findings highlight not just the potential of modern pharmaceuticals, but also the enduring importance of human behaviour in the treatment of chronic disease.

With regulatory decisions on the horizon, all eyes are now on semaglutide—and the hope it offers to the millions affected by MASH.

Would you like a visual infographic to go along with this article?

Conclusion

The latest clinical trial results for semaglutide mark a significant step forward in the search for an effective treatment for MASH, a progressive liver disease with no approved therapies currently available in the European Union. While the findings are undeniably promising—showing improvements in liver inflammation, scarring, and body weight—experts caution that semaglutide is not a standalone solution. Lifestyle changes remain essential to achieving long-term health benefits.

As regulatory bodies consider approving semaglutide for MASH, this development offers renewed hope for patients living with the disease. However, the ultimate impact will depend on how well patients and healthcare systems integrate this drug with comprehensive lifestyle and metabolic care. If used responsibly and in the right context, semaglutide could become a powerful tool in transforming how MASH is managed and potentially prevented.